Tigatuzumab Antibody

SKU: orb1980650

Description

Tigatuzumab (CS-1008) is a humanized agonistic monoclonal antibody targeting Death Receptor 5 (DR5/TRAIL-R2) to induce apoptosis in tumor cells. It has been investigated in preclinical and clinical studies, particularly for pancreatic cancer research, demonstrating activity in both in vitro and in vivo models.

Research Area

Cell Biology

Images & Validation

−

Key Properties

−

CAS Number	918127-53-4
MW	144.6 (kDa)
Purity	95.00%
Target	TNF,Apoptosis

Bioactivity

−

Target IC50	MIAPaCa2 cells:2.95 μg/mL
In Vivo	Tigatuzumab (3 mg/kg; i.v.; once weekly for 4 weeks) was effective in inhibiting tumor growth of human pancreatic cancer MIA PaCa-2-RFP in a xenograft mouse model. Read more...
In Vitro	Tigatuzumab showed sensitivity to MIA PaCa-2 cells and BxPC-3 cells with IC50 values of 2.95 μg/mL and 8.21 μg/mL, respectively. Tigatuzumab (3-8 μg/mL; 5 hours) was able to induce apoptosis in cancer cells. Read more...

Storage & Handling

−

Storage	Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Expiration Date	12 months from date of receipt.
Disclaimer	For research use only

Alternative Names

−

Anti-Human TRAIL-R2 Recombinant Antibody, CS1008, CS-1008, TRA8, TRA-8

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at support@biorbyt.com.

Quick Database Links

Gene Symbol

TNF,Apoptosis

Documents Download

Datasheet

Product Information

Download

Request a Document

Protocol Information

Find More Protocols